Navigation Links
IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Date:3/20/2008

ince the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including the objectives of the compassionate access study, the Company's plans to address the remaining questions with respect to the MAA during the clock-stop granted by the CHMP, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA in the European Union, as well as the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE, including the expected timing for such an amended NDA, and to respond to other matters raised by the FDA and plans to evaluate strategic alternatives. Actual results may differ materially from the forward- looking statements due to a number of important factors, including, but not limited to, whether the compassionate access study will generate data that is consistent with data from previous studies with L-MTP-PE or result in improvement in disease control and quality of life for participants in the study, whether the Company will be able to provide assurance regarding the quality of the existing data and to respond to the remaining issues with regard to the MAA, including ver
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
9. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Fortune Oil and Gas, Inc. (OTCPink:FOGC), today announced that ... Inc. with the symbol (OTCPink : FOGCD). FINRA approved ... Also taking effect today is a ten for 1 ... event in the company,s progress according to CEO, ... proceed with the plan and still have any level ...
(Date:9/17/2014)... , Sept. 17, 2014  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that agreement has been reached ... on the design of a pivotal, Phase 3 ... for the treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... , 17 settembre 2014 Hologic, Inc. ... il lancio in Europa del Tomcat, un nuovo ... una piattaforma multifunzionale completamente automatizzata, progettata per semplificare ... ed i rischi di errore legati alla gestione ... strumento Tomcat di Hologic riduce il carico di ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
... Reportlinker.com announces that a new market research report is ... http://www.reportlinker.com/p0484924/Epidemiology-Lupus.html In ... cases of systemic lupus erythematosus (SLE) in the seven ... women between 45 and 64 years of age. The ...
... NEW YORK, April 26, 2011 Reportlinker.com announces that ... catalogue: Epidemiology: Prostate Cancer ... period, prostate cancer incident cases will increase in all ... likely to be as a result of an aging ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Lupus 2Reportlinker Adds Epidemiology: Prostate Cancer 2
(Date:9/17/2014)... 17, 2014 The global metrology services ... due to the key driving factors of increasing demands ... CAGR of 8.2 % puts the metrology services market ... 2018, as stated in a Transparency Market Research report ... Share, Growth, Trends, and Forecast 2012 – 2018”. , ...
(Date:9/17/2014)... This news release is available in Spanish . ... overweight affect more than half of the population in ... organism, one of which affects liver function. Fat accumulates ... circumstances, causes inflammation, fibrosis and finally, cirrhosis. To date, ... been hepatic biopsy. Imaging techniques such as abdominal ecography ...
(Date:9/17/2014)... (GSA) invites all journalists to attend its ... interdisciplinary conference in the field of aging from ... may register free of charge. , An estimated 4,000 ... the Walter E. Washington Convention Center and Marriott Marquis ... From Cells to Societies" and the program schedule contains ...
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Neon Sport and Fitmark have an ... industry’s most anticipated event, Joe Weider's Olympia Fitness & ... each take home a Neon Sport branded Fitmark Power ... gear. Fitmark will hold entries for the special prize ... , “There’s nothing more exciting than seeing our ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... anti-HLA antibody assays both contribute to characterization ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed by Cylex ... the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated immunity and ...
... also helped with severe fatigue among patients on chemotherapy ... the more common and unpleasant side effects of treatment ... by the ancient Chinese practice of acupuncture. , A ... and pain and shoulder dysfunction after neck dissection in ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... VA Three new studies published in the June ... focus on what role gender plays in the prognosis ... and the success rates of hearing aid implants in ... the wide variety of critical research being undertaken every ...
... pancreatic, kidney cancers, respectively , , SATURDAY, May ... cancer -- which historically carries a grim prognosis ... cancer drug Gemzar was used after surgery, new ... of pancreatic cancer patients are even candidates for ...
... death for female survivors; cardiovascular events for males ... survived Hodgkin lymphoma as children have an increased risk ... disease as adults, according to a new report. ... -- may help drive these increased risks, according to ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2
... WardWatch has been designed specifically ... medical staff involved in ward rounds. ... medications and dosages, and consultations that ... (Specialist) or Registrar during Ward round ...
... is an advanced medical calculator ... Pediatric Dosing and Critical Care ... a logical complement to other ... the Daviss Drug Guide, PDR ...
... comprehensive guide provides safe, effective, ... information in a quickly accessible ... edition includes the latest drugs ... key nursing implications are highlighted ...
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
Medicine Products: